13 Feb 2023 , 09:31 AM
Sun Pharma Industries Limited informed that it is recalling more than 34,000 bottles of generic medication in the US market due to failed dissolution testing. This medicine is used to treat high blood pressure.
According to the US Food and Drug Administration’s Enforcement Report, Sun Pharmaceutical Industries’ US-based arm is recalling large quantities of Diltiazem Hydrochloride extended-release capsules, which are used to treat angina, some types of irregular heartbeats, and high blood pressure.
The pharmaceutical company located in New Jersey has taken the decision to recall a specific batch of their product due to a failure in impurity control (Deacetyl Diltiazem Hydrochloride) during stability tests, as well as subpar results in dissolution testing as determined by the USFDA’s laboratory.
The lot was manufactured at the Mumbai-based drugmaker’s Halol-based manufacturing facility in Gujarat. The affected lot was later supplied in the market by the company’s US-based subsidiary.
On January 13, this year, the company began the Class II nationwide recall (US).
The USFDA explains that a Class II recall is called into action when a product that violates their standards may result in health problems that can be fixed with medical intervention, or when the likelihood of severe health consequences is low.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.